Position in GPCR
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$2,284,730
+$357,502 QoQ
Shares Held
42,570
+6.5% QoQ
Ownership
0.060%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#84
of 190 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GPCR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BANK OF MONTREAL /CAN/ holds $701,516,965 across 82 Biotechnology names. GPCR ranks #24 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
427,448 | $212,326,240 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
942,432 | $73,764,150 | |
| 3 | ARGX |
Argenx SE
|
77,213 | $71,635,902 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
103,247 | $64,378,631 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
242,063 | $58,329,919 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
515,981 | $28,347,995 | |
| 7 | MRNA |
Moderna, Inc.
|
389,789 | $27,296,921 | |
| 8 | CYTK |
Cytokinetics Inc
|
285,688 | $24,337,759 |
All Filings in GPCR
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,284,730 | 42,570 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $1,927,228 | 39,984 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $3,779,416 | 54,341 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $1,700,216 | 60,722 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $1,204,433 | 58,073 | Shares | Defined | 2025-08-05 | |
| 2025-03-31 | $921,497 | 53,235 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $1,360,691 | 50,173 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $2,040,972 | 46,502 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $1,063,981 | 27,094 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||